ENPICOM receives a €1.13 million follow-on investment

BOM Brabant Ventures, NextGen Ventures, and Arches Capital reach an agreement with the founders for a follow-on investment to scale ENPICOM’s immunomics activities

May 20, 2020

Bioinformatics software engineering company ENPICOM has closed a follow-on investment round with its series A investors: BOM Brabant Ventures, Nextgen Ventures, and Arches Capital. They jointly invested another €1.13 million in excess of the original Series A amount of €1.2 million to further support the company’s ambition to become a global player in the field of immunomics data analysis.

ENPICOM series A investors

It’s great to be able to announce this follow-on investment today,” said CEO Jos Lunenberg. “It confirms the trust our team has gained in the past one and half year of our investors by executing on the agreed strategies according to plan and serves as evidence of our successful company setup. This additional capital injection allows us to scale our commercial activities, further develop our Research Use Only platform and start serving additional market segments in the near future.”

ENPICOM BV, founded in 2017, has developed a unique cloud-based SaaS platform to streamline the analysis and management of vast amounts of repertoire sequencing data, accelerating the discovery and development of novel immunotherapies and vaccines. The IGX Platform is the only end-to-end solution on the market to efficiently manage, analyze, visualize, and compare T and B cell receptor sequencing data with any other type of data. With powerful data handling features, an intuitive user interface, and a growing set of analysis apps, the platform empowers scientists in academic research centers and biopharmaceutical companies to accurately interpret large-scale repertoire data, reduce the time needed to extract biologically and clinically relevant insights, and, most importantly, unlock insights that otherwise would have stayed hidden.

In April 2019, the first version of the platform was launched and earlier this year, in March, ENPICOM introduced the IGX Platform 2.0, the second major release supporting single-cell sequencing data integration. The ability to manage and analyze data from bulk and single-cell workflows in one environment provides unprecedented opportunities for immunomics research and drug development. ENPICOM’s IGX Platform streamlines the analysis process, effectively minimizing the data integration difficulties and maximizing the scientific output. Another important new feature added in the latest version of the platform is the IGX-Compare App, which was introduced at a very crucial moment in time. Since it allows users to compare any two data sets and easily visualize and prioritize matching clones, for instance, by matching a single clone against an external database or by finding the overlap between two internal patient cohorts, the App was well received by researchers working on COVID-19 vaccines and antibody-based treatments.